Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Takeaway Points: To diagnose chronic lymphocytic leukemia (CLL), there needs to be ≥5000 monoclonal (genetically identical) B-lymphocytes (a type of white blood cell) in the blood for the duration of at
Clinician Resource Library: Topical Handouts Click below on each of the topical handouts to either print copies on demand or order copies in bulk that will be shipped free of charge. Please
NX-2127 is a new type of drug that degrades BTK. Phase 1 clinical trial data shows that it has a manageable safety profile in patients with CLL / SLL.
Five years after completing venetoclax – obinutuzumab to treat chronic lymphocytic leukemia (CLL), over half of the treatment-naive patients remained in remission, and over 60% did not require second-line treatment, including many high-risk patients.
Acalabrutinib and zanubrutinib have similar excellent efficacy in relapsed or refractory chronic lymphocytic leukemia (CLL).
Atezolizumab, obinutuzumab, and venetoclax combination therapy is active in patients with untreated DLBCL-Richter’s Syndrome (RS).
Join Dr. Koffman as he and Dr. Adrian Wiestner discuss A New Oral BTK Protein Degrader: A novel drug designed to overcome resistance to BTK Inhibitors.
A newly published paper in the New England Journal of Medicine found that pirtobrutinib shows efficacy in patients with heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had received a covalent Bruton tyrosine kinase inhibitor (BTKi).
Pirtobrutinib is a new BTK inhibitor that binds differently (non-covalently) to BTK than the three approved BTK inhibitors, ibrutinib, acalabrutinib, and zanubrutinib.
One click to our most popular content.
